MedCity News May 11, 2022
Nuvig Therapeutics is developing drugs that tap into one of the body’s natural mechanisms for controlling inflammation. Co-founder and CEO Pamela Conley, a veteran of Portola Pharmaceuticals, says Nuvig’s approach could offer efficacy similar to currently available autoimmune drugs but with a better safety profile.
Autoimmune disease drugs work by addressing a protein or pathway associated with inflammation, targeting it to suppress the excessive immune response. Such drugs can treat a range of conditions, but they also introduce safety risks—an ongoing problem as the chronic nature of these diseases mean that patients are on treatment for the long term. Nuvig Therapeutics is taking a different tack, tapping into a built-in way that the immune system resets. The biotech startup is...
Today's Sponsors
Today's Sponsor